A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2862 participants.

Also called NCT06642623

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,862 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06642623
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06642623. Randomized; no masking; primary purpose treatment. Start 2024-01-22 (actual); primary completion 2029-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients
Acronym
ENVELOP
Condition
Diabetes Mellitus, Type 2
Condition
Cardiovascular Diseases
Condition
Kidney Diseases
Intervention (Drug)
Enavogliflozin
Intervention (Drug)
Dapagliflozin or Empagliflozin
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct06642623
Content hash
59554baba6a61c7301a46200b795e5c79bf9b892537b7fa84e98833b93143c45